Daiichi Sankyo and ArQule Enroll First Hepatocellular Carcinoma Patient into Global Phase 3 Trial for Tivantinib

[Business Wire] – TOKYO & WOBURN, Mass.–(BUSINESSWIRE)– Daiichi Sankyo Company, Limited (TSE 4568) and ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient has been enrolled in the pivotal Phase 3 METIV-HCC … more

View todays social media effects on ARQL

View the latest stocks trending across Twitter. Click to view dashboard

See who ArQule is hiring next, click here to view